Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Integra LifeSciences Holdings CorporationNASDAQ: IART
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA growth accelerates
Q1 FY2026 EBITDA of $62.87M rose 142.1% year over year, ahead of the -260.5% change in trailing-twelve-month EBITDA. Sequentially, it fell 4.7% from the prior quarter.
Context
- EBITDA amounted to 19.9% of revenue in FY2025, up 7.9 pp from a year earlier.
- EBITDA increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of $443.93M (+236.1%) for the fiscal year ending Dec 2026, a step up from the -268.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $62.87M-4.7% QoQ
- Last fiscal yearDec 2025
- -$326.2M-268.8% YoY
- LTMMar 2026
- -$289.3M-260.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +142.1% | +123.6% | -18.5 pp |
| 1 year | -268.8% | +236.1% | +504.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (326.2M) USD
- Year-over-year change
- -268.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (326.2M) | -268.8% |
| FY2024 | 2024-12-31 | 193.29M | -24.5% |
| FY2023 | 2023-12-31 | 255.96M | -33.4% |
| FY2022 | 2022-12-31 | 384.6M | +5.0% |
| FY2021 | 2021-12-31 | 366.33M | — |
EBITDA vs competitors
How IART compares with its peers on the latest reported figures
- IART's LTM Mar 2026 EBITDA of -$289.3M is the lowest of the 11 companies compared; the peer median is $79.78M.
- Its year-over-year change of -260.5% is the lowest of 11, against a peer median of +46.8%.
- EBITDA amounts to 17.6% of revenue for IART, versus a peer median of 13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.69B | +40.7% | +16.3% | 25.9% | |
| FY2025 | $1.34B | +0.1% | +5.1% | 21.7% | |
| LTM Jun 2026 | $945.76M | +52.8% | +42.8% | 30.1% | |
| LTM Mar 2026 | $169.63M | -31.6% | +170.6% | 12.4% | |
| LTM Mar 2026 | $94.51M | +693.8% | — | 11.5% | |
| LTM Mar 2026 | $65.05M | +84.5% | +35.4% | 14.2% | |
| LTM Mar 2026 | $11.81M | +465.2% | — | 9.7% | |
| LTM Mar 2026 | -$1.36M | +97.4% | — | 0.2% | |
| LTM Sep 2026 | -$21.24M | -198.3% | — | 8.0% | |
| LTM Jun 2026 | -$33.12M | +4.6% | — | 41.4% | |
| LTM Mar 2026 | -$289.3M | -260.5% | — | 17.6% | |
| Peer median (excluding IART) | $79.78M | +46.8% | +35.4% | 13.3% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B |
| Cost of Revenue | 597.81M | 587.36M | 656.84M | 728.47M | 790.01M |
| Gross Profit | 944.64M | 970.31M | 884.74M | 882.06M | 845.23M |
| Gross Margin | 61.2% | 62.3% | 57.4% | 54.8% | 51.7% |
| Research & Development | 93.05M | 101.19M | 104.19M | 115.38M | 98.97M |
| Selling, General & Admin | 637.45M | 616.32M | 656.64M | 716.98M | 699.7M |
| Operating Expenses | 747.41M | 731.39M | 773.21M | 853.65M | 776.92M |
| Depreciation & Amortization | 123.67M | 121.12M | 123.51M | 140.5M | 151.05M |
| EBITDA | 366.33M | 384.6M | 255.96M | 193.29M | (326.2M) |
| EBITDA Margin | 23.7% | 24.7% | 16.6% | 12.0% | -19.9% |
| Operating Income | 197.23M | 238.92M | 111.53M | 28.41M | 68.32M |
| Operating Margin | 12.8% | 15.3% | 7.2% | 1.8% | 4.2% |
| Interest Income | 6.74M | 11.92M | 17.2M | 20.04M | 18.47M |
| Interest Expense | 50.4M | 49.59M | 51.38M | 70.63M | 86.26M |
| Other Income / Expenses | 17.45M | (25.03M) | (30.46M) | (46.65M) | (631.82M) |
| Income Before Tax | 214.68M | 213.89M | 81.07M | (18.24M) | (563.5M) |
| Pre-Tax Margin | 13.9% | 13.7% | 5.3% | -1.1% | -34.5% |
| Income Tax Expense | 45.6M | 33.34M | 13.33M | (11.29M) | (47.03M) |
| Net Income | 169.08M | 180.55M | 67.74M | (6.94M) | (516.47M) |
| Net Margin | 11.0% | 11.6% | 4.4% | -0.4% | -31.6% |
| EPS (Basic) | 2.00 | 2.18 | 0.87 | (0.09) | (6.73) |
| EPS (Diluted) | 1.98 | 2.16 | 0.84 | (0.09) | (6.73) |
| Weighted Avg Shares | 84.7M | 83M | 78.17M | 77.01M | 76.75M |
| Weighted Avg Shares (Diluted) | 85.49M | 83.52M | 80.34M | 77.01M | 76.75M |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.